Introduction {#intro}
============

Corrosion and wear of THA liberates metal, polyethylene, and methacrylate particles. According to post-mortem and in vivo studies, such metal particles are widely dispersed in the body and have been found in the liver, the spleen, and in local and distant lymph nodes ([@CIT0018], [@CIT0003], Eng et al. 1997, [@CIT0030], [@CIT0034], [@CIT0035]). Thus, patients with metal-on-polyethylene (MP) bearings are permanently exposed to Cr, Co, and Ti ions more extensively than healthy controls ([@CIT0016], [@CIT0028], [@CIT0020], [@CIT0026]).

Both in vivo and in vitro studies have shown chromosomal aberrations and DNA damage in association with debris from CoCr and TiAlV prostheses. Bone marrow adjacent to the worn implant was found to show an increased number of chromatid breaks and gaps ([@CIT0004]). At revision THA, patients with mixed types of CoCr prostheses had a 2.5-fold increase in peripheral blood lymphocytes with aneuploidy and 3.5 fold more chromosomal translocations than at primary THA ([@CIT0009]). Wear debris from worn hip and knee prostheses in human tissue cultures has been found to damage chromosomes in a dose-dependent manner, which was specific to the type of metal. A correlation was found between Co and Cr concentrations on the one hand and chromosomal breakage and aneuploidy on the other; similarly, there was a correlation between Ti concentrations and aneuploidy ([@CIT0007]). [@CIT0008] showed that synovial fluid from revised CoCr metal-on-metal (MM) and MP prostheses caused DNA damage to human fibroblast culture cells, which was believed to be a synergistic effect of Co and Cr ions. Wear debris from a worn TiAlV MP prosthesis has been found to produce chromosomal instability in human fibroblast cell cultures ([@CIT0005]). Further genomic instability was evident when the progeny of the cells were exposed to low doses of wear debris. Chromosomal aberrations associated with metallic ions can be predictive of cancerogenesis ([@CIT0002]) and an increased risk of cancer in THA patients. Latent periods of 10 or more years are required for the development of particle-, virus-, or industrial metal-induced cancers ([@CIT0040], [@CIT0041], [@CIT0001]). We investigated the long-term risks for all and site-specific cancers in primary THA patients with MP prostheses by updating our previous cohort study from the Finnish Endoprosthesis Register (Paavolainen et al. 2000).

Patients and methods {#ss2}
====================

The data from the Finnish Arthroplasty Register was linked with that from the Finnish Cancer Registry, and records of all cancer cases were obtained from 1980 through 2005. The original cohort comprised 33,694 patients, 24,636 of whom were operated on for primary osteoarthritis (OA). All patients were provided with MP prostheses, and 71% of the femoral components and 65% of the acetabular components were cemented. The stem material was cobalt chrome molybdenum (CoCrMo) in about 40% of the prostheses, titanium aluminium vanadium (TiAlV) in 36%, and stainless steel (SS) in 24% ([@CIT0022]2000).

The patients were followed up for cancer incidence from the date of first operation until death, or until 31 December 2005. The follow-up time was up to 25 years with a mean of 12.6 years. The follow-up was not stopped at the date of first diagnosis of cancer, but all primary cancers diagnosed during the follow-up period were counted as observed cases. The numbers of observed cases for each cancer and person-years at follow-up were stratified by sex, calendar period and 5-year age group, and follow-up time since the operation. The expected number of each cancer type was calculated by applying the number of person-years in each stratum to the corresponding cancer incidence rate in the Finnish population. The calendar periods used were 1980--1986, 1987--1993, 1994--1999, and 2000--2005, and the follow-up categories were 0--2, 3--9, 10--20, and \> 20 years since the operation. Only 97 patients (0.04%) were followed for more than 20 years. The relative risk of cancer was expressed as the ratio of observed and expected number of cases, i.e. standardized incidence ratio (SIR). The 95% confidence intervals (95% CIs) were defined assuming that the number of observed cases followed a Poisson distribution.

Results {#ss3}
=======

The cohort yielded 310,341 person-years, which is approximately twice as much as in the previous analysis (Paavolainen et al. 2000). The proportion of male patients was 38% ([Table 1](#T1){ref-type="table"}). Altogether, 13,324 patients (54%) had died before the end of 2005. There were no losses to follow-up.

###### 

Numbers of patients (n) by age at operation, and number of person-years at end of follow-up

  Age      Men     Women              
  -------- ------- --------- -------- ---------
  15--29   10      35        11       44
  30--44   156     784       168      906
  45--59   2,060   11,144    2,214    11,796
  60--74   5,751   57,484    9,214    83,132
  ≥ 75     1,502   43,861    3,550    101,155
  Total    9,479   113,308   15,157   197,033

The overall SIR for all-site cancers was 0.95 (95% CI: 0.92--0.97) ([Table 2](#T2){ref-type="table"}). After the first 2 postoperative years with very low all-site cancer incidence (SIR = 0.80; 95% CI: 0.73--0.87), the SIR rose to 0.97 (95% CI: 0.94--1.00) ([Table 3](#T3){ref-type="table"}).

###### 

Observed (Obs) numbers of cancer cases and standardized incidence ratios (SIRs) with 95% confidence intervals, by site

  Primary site                    Obs    SIR    95% CI
  ------------------------------- ------ ------ --------------------
  All sites                       4846   0.95   0.92--0.97 **^a^**
  Lip                             50     1.19   0.88--1.56
  Mouth, pharynx                  104    1.09   0.89--1.30
  Esophagus                       49     0.81   0.60--1.06
  Stomach                         245    0.95   0.84--1.07
  Colon                           310    0.89   0.79--0.99 **^b^**
  Rectum                          193    0.91   0.79--1.04
  Liver                           65     0.87   0.67--1.11
  Gall bladder                    86     1.01   0.81--1.24
  Pancreas                        201    0.90   0.78--1.02
  Larynx                          19     0.80   0.48--1.25
  Lung                            368    0.65   0.58--0.71 **^a^**
  Breast                          515    1.00   0.92--1.08
  Uterus, cervix                  28     1.03   0.68--1.48
  Uterus, corpus                  134    0.94   0.79--1.10
  Ovary                           86     0.94   0.75--1.16
  Prostate                        843    1.09   1.02--1.16 **^b^**
  Kidney                          180    1.08   0.93--1.24
  Bladder,ureter, urethra         222    0.98   0.86--1.11
  Melanoma                        97     0.99   0.80--1.20
  Skin                            279    1.07   0.95--1.20
  Brain/nervous system            103    0.97   0.79--1.16
  Thyroid                         38     1.06   0.75--1.45
  Bone                            3      0.72   0.15--2.10
  Connective tissue               24     0.90   0.58--1.34
  Non-Hodgkin\'s lymphoma         167    0.92   0.79--1.06
  Nodal non-Hodgkin\'s lymphoma   98     0.81   0.66--0.98 **^b^**
  Hodgkin\'s lymphoma             13     1.26   0.67--2.15
  Myeloma                         90     1.14   0.92--1.40
  Leukemia                        96     0.85   0.69--1.03

###### 

Observed (Obs) numbers of cancer cases and standardized incidence ratios (SIR) with 95% confidence intervals (CI), by site and the time since the first total hip arthroplasty

  Primary site                                       Time since operation                                                                              
  ---------------- ----- ------ -------------------- ---------------------- ------ -------------------- ------ ------ -------------------- ---- ------ --------------------
  All sites        492   0.80   0.73--0.87 **^a^**   2560                   0.95   0.92--0.98 **^b^**   1697   0.99   0.94--1.03           97   0.93   0.75--1.12
  Stomach          31    0.82   0.55--1.15           134                    0.95   0.80--1.11           79     1.07   0.85--1.33           1    0.24   0.01--1.34
  Colon            30    0.79   0.53--1.12           165                    0.92   0.78--1.06           107    0.87   0.72--1.04           8    1.01   0.44--1.98
  Rectum           19    0.72   0.43--1.12           111                    0.98   0.81--1.17           59     0.86   0.66--1.11           4    0.98   0.27--2.51
  Pancreas         21    0.78   0.48--1.18           111                    0.95   0.78--1.13           62     0.82   0.63--1.05           7    1.41   0.57--2.90
  Lung, trachea    40    0.48   0.34--0.65 **^a^**   204                    0.66   0.57--0.75 **^a^**   115    0.70   0.57--0.82 **^a^**   9    1.00   0.46--1.89
  Breast           69    1.02   0.79--1.29           264                    0.96   0.85--1.08           177    1.08   0.93--1.24           5    0.49   0.16--1.14
  Female genital                                                                                                                                       
  organs           40    0.97   0.69--1.32           152                    0.95   0.80--1.10           82     0.88   0.70--1.09           5    0.88   0.29--2.05
  Kidney           20    0.91   0.56--1.41           100                    1.11   0.90--1.34           55     1.05   0.79--1.36           5    1.65   0.53--3.84
  Prostate         56    0.81   0.61--1.05           433                    1.10   1.00--1.20           335    1.14   1.02--1.26 **^b^**   19   1.16   0.70--1.80
  Melanoma         10    0.88   0.42--1.61           50                     0.99   0.74--1.30           33     0.97   0.67--1.36           4    1.84   0.50--4.71
  \>Lymphoma,                                                                                                                                          
  leukemia         41    0.68   0.49--0.92           265                    1.00   0.88--1.13           153    1.11   0.94--1.30           2    0.19   0.20--0.70 **^b^**

After 10 and 20 years of follow-up, the all-site cancer incidence was similar to that in the general population with a SIR of 0.98 (95% CI: 0.94--1.03) and 0.93 (95% CI: 0.75--1.12), respectively. Female patients had higher SIR values than male patients during the first 2 years (0.91 (95% CI: 0.81--1.01) vs. 0.69 (95% CI: 0.60--0.78)), and between years 3 and 9 postoperatively (0.98 (95% CI: 0.92--1.02) vs. 0.93 (95% CI: 0.88--0.98)). These higher SIR values were mainly due to breast cancer and female genital cancers. The corresponding SIR values in the general population were, however, similar from the beginning and throughout the whole study period ([Table 3](#T3){ref-type="table"}). Site-specific cancers, except for lung, colon, prostate cancer and non-Hodgkin\'s lymphoma, had SIR values that were similar to those in the normal population ([Table 2](#T2){ref-type="table"}). Lung cancer incidence was low in the male patients throughout the whole follow-up period (with SIR values of 0.35--0.84) ([Table 3](#T3){ref-type="table"}).

SIR for kidney cancer was relatively high already during the first postoperative year and increased slightly thereafter ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). A slight excess of prostate cancers was observed between years 10 and 19 (SIR = 1.14) and also during the whole follow-up (SIR = 1.09) ([Table 3](#T3){ref-type="table"}). The SIR for bone and soft tissue sarcomas was 0.77 (95% CI: 0.51--1.12).

A slight increase in hematopoetic cancers (SIR = 1.11) was observed between years 10 and 19 postoperatively, which was due to an increase in multiple myelomas and Hodgkin lymphomas. SIRs for all hematopoetic cancers were similar to those in the normal population (0.97). The SIRs for non-Hodgkin\'s lymphomas and leukemia remained below (1.00) during the whole follow-up time, whereas those for multiple myeloma ranged from 1.00 to 1.19, and those for Hodgkin\'s lymphoma from 1.13 to 1.38 after the twentieth postoperative year.

Discussion {#ss4}
==========

The patients in our cohort were exposed to the degradation products of the most common metal alloys used: CoCrMo, TiAlV, or SS alloy, but cement usage and different metal compositions and cancer risk were not studied because these data were not available per hip or per patient in the study material.

The overall cancer risk seen in this study (SIR = 0.95) was the same level (SIR = 0.98) to that seen in a large meta-analysis on THA patients with 1,094 000 person-years and operated on for all indications, but with a mean follow-up time of only 6 years ([@CIT0023]). The same findings were reported by Goldachre et al. (2005) from the UK after an average of 8 years of follow-up of 33,691 patients who were operated for all indications. The SIR of 0.92 in our cohort during the first 10 years is equal to that (0.93) observed in a Nordic meta-analysis in patients who were operated on for OA with 374,000 person-years and with a mean follow-up time of 8 years ([@CIT0037]). In one study, OA has been reported to be associated with low cancer co-morbidity: [@CIT0032] reported a low all-site cancer incidence (0.85 for males and 0.83 for females) in patients with all forms of OA in a Scottish cohort.

Pre-screening of our patients for surgery decreased the cancer incidence in a comparison with the normal population approximately for 10 years indicating a long latent period. We found 20% less cancer cases than in a comparative sample of the general Finnish population during the 2 postoperative years, but after 11 years of follow-up the cancer incidence rate were equalized.

Lung cancer incidence in the male patients was low throughout the whole follow-up period. It is well known that tobacco smoking is the cause of lung cancer in 90% of cases (Tyczynsky et al. 2003). A low incidence of lung cancer was reported in a meta-analysis involving THA patients operated on for primary osteoarthritis (SIR = 0.69) ([@CIT0037]). In THA patients operated on for all indications, the SIR for lung cancer was found to be 0.82 ([@CIT0023]), which was similar to the value from a large British cohort (0.86) (Goldachre et al. 2005). In 1,495 male Swedish constructors who smoked, the risk of severe osteoarthritis of the hip requiring surgery was found to be lower than in non-smokers or ex-smokers ([@CIT0017]). Also, a significantly lower risk of hip osteoarthritis was found in 210 men who were current cigarette smokers than in men who had never smoked and who were listed for THA ([@CIT0006]). This association was not observed in women. [@CIT0036] observed a reversed risk in 230 women who had undergone a THA operation.

Special interest lay in the occurrence of hematopoetic malignancies, given the high number of these cancers reported in earlier studies ([@CIT0012], [@CIT0038]). The reticuloendothelial system is especially loaded with wear debris ([@CIT0018], Case et al.1996). In vivo studies on lymphocytes in THA patients, both patients with TiAlV and with CoCr prostheses, showed that they had chromosomal aberrations ([@CIT0031], [@CIT0009]). In addition, patients with MP bearings had a reduced number of peripheral T lymphocytes ([@CIT0014]). In our study, lymphomas and leukemias showed slightly increased SIR values until 20 years of follow-up, and after that a decrease to 0.19---but with only 2 cases observed and 10.5 cases expected. The incidence of sarcoma was low, and to our knowledge, our series did not include any tumor at the site of the prosthesis. Despite the vast number of implanted THAs, only 52 malignant tumors located close to an arthroplasty (46 sarcomas, 5 lymphomas, and 1 epidermoid carcinoma) have been reported in the western literature ([@CIT0019], [@CIT0029], [@CIT0039], [@CIT0015], [@CIT0021]).

Until now, meta-analyses on the risk of cancer after THA have shown that the patients can effectively resist the genotoxic effects of Co and Cr particles and ions and the possible development of cancer ([@CIT0037], Onega et. al 2006). Co and Cr are essential trace elements, and one can assume that the cells have inherited efficient repair systems for DNA damage caused by these elements ([@CIT0027]). In addition, macrophages have been shown to counteract the genotoxic and cytotoxic effects of CoCr particles in vitro ([@CIT0025]).

Our study with a mean follow-up time of 12.6 years did not show any all-site or site-specific risk of cancer in patients with conventional THA, and most THA patients will outlive any possible latent period for cancer. However, a 20--40-year latent period is known to be required for some solid malignant tumors ([@CIT0040], [@CIT0041], [@CIT0001]). As this survey may have been too short to ascertain the risk of cancer in young patients expected to use their THA prostheses for more than 30 years, analyses with even longer follow-up times are still needed.
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